> 0 1 0 1 O
= 1 2 1 2 O
42 3 5 3 5 B-lower_bound
days 6 10 6 10 I-lower_bound
if 11 13 11 13 O
other 14 19 14 19 O
substantial 20 31 20 31 O
bone 32 36 32 36 B-treatment
marrow 37 43 37 43 I-treatment
( 44 45 44 45 I-treatment
BM 45 47 45 47 I-treatment
) 47 48 47 48 I-treatment
radiation 49 58 49 58 I-treatment

Age 0 3 59 62 B-age
1 4 5 63 64 B-lower_bound
to 6 8 65 67 O
< 9 10 68 69 O
2 11 12 70 71 B-upper_bound
years 13 18 72 77 I-upper_bound
: 18 19 77 78 O
maximum 20 27 79 86 O
serum 28 33 87 92 B-clinical_variable
creatinine 34 44 93 103 I-clinical_variable
( 45 46 104 105 O
mg 46 48 105 107 O
/ 48 49 107 108 O
dL 49 51 108 110 O
) 51 52 110 111 O
0.6 53 56 112 115 B-upper_bound
for 57 60 116 119 O
males 61 66 120 125 B-gender
and 67 70 126 129 I-gender
females 71 78 130 137 I-gender

Age 0 3 138 141 B-age
10 4 6 142 144 B-lower_bound
to 7 9 145 147 O
< 10 11 148 149 O
13 12 14 150 152 B-upper_bound
years 15 20 153 158 I-upper_bound
: 20 21 158 159 O
1.2 22 25 160 163 B-upper_bound
for 26 29 164 167 O
males 30 35 168 173 B-gender
and 36 39 174 177 O
females 40 47 178 185 B-gender

Age 0 3 186 189 B-age
13 4 6 190 192 B-lower_bound
to 7 9 193 195 O
< 10 11 196 197 O
16 12 14 198 200 B-upper_bound
years 15 20 201 206 I-upper_bound
: 20 21 206 207 O
1.5 22 25 208 211 O
for 26 29 212 215 O
males 30 35 216 221 B-gender
and 36 39 222 225 O
1.4 40 43 226 229 O
for 44 47 230 233 O
females 48 55 234 241 B-gender

Age 0 3 242 245 B-age
2 4 5 246 247 B-lower_bound
to 6 8 248 250 O
< 9 10 251 252 O
6 11 12 253 254 B-upper_bound
years 13 18 255 260 I-upper_bound
: 18 19 260 261 O
0.8 20 23 262 265 B-upper_bound
for 24 27 266 269 O
males 28 33 270 275 B-gender
and 34 37 276 279 O
females 38 45 280 287 B-gender

Age 0 3 288 291 B-age
6 4 5 292 293 B-lower_bound
to 6 8 294 296 O
< 9 10 297 298 O
10 11 13 299 301 B-upper_bound
years 14 19 302 307 I-upper_bound
: 19 20 307 308 O
1 21 22 309 310 O
for 23 26 311 314 O
males 27 32 315 320 B-gender
and 33 36 321 324 O
females 37 44 325 332 B-gender

Age 0 3 333 336 B-age
> 4 5 337 338 O
= 5 6 338 339 O
16 7 9 340 342 B-lower_bound
years 10 15 343 348 I-lower_bound
: 15 16 348 349 O
1.7 17 20 350 353 O
for 21 24 354 357 O
males 25 30 358 363 B-gender
and 31 34 364 367 O
1.4 35 38 368 371 O
for 39 42 372 375 O
females 43 50 376 383 B-gender

Allogeneic 0 10 384 394 B-treatment
( 11 12 395 396 I-treatment
non 12 15 396 399 I-treatment
- 15 16 399 400 I-treatment
autologous 16 26 400 410 I-treatment
) 26 27 410 411 I-treatment
bone 28 32 412 416 I-treatment
marrow 33 39 417 423 I-treatment
or 40 42 424 426 I-treatment
stem 43 47 427 431 I-treatment
cell 48 52 432 436 I-treatment
transplant 53 63 437 447 I-treatment
, 63 64 447 448 O
or 65 67 449 451 O
any 68 71 452 455 O
stem 72 76 456 460 B-treatment
cell 77 81 461 465 I-treatment
infusion 82 90 466 474 I-treatment
including 91 100 475 484 I-treatment
donor 101 106 485 490 I-treatment
lymphocyte 107 117 491 501 I-treatment
infusion 118 126 502 510 I-treatment
( 127 128 511 512 I-treatment
DLI 128 131 512 515 I-treatment
) 131 132 515 516 I-treatment
or 133 135 517 519 I-treatment
boost 136 141 520 525 I-treatment
infusion 142 150 526 534 I-treatment
: 150 151 534 535 O
> 152 153 536 537 O
= 153 154 537 538 O
100 155 158 539 542 B-lower_bound
days 159 163 543 547 I-lower_bound
after 164 169 548 553 O
infusion 170 178 554 562 O
, 178 179 562 563 O
no 180 182 564 566 O
evidence 183 191 567 575 O
of 192 194 576 578 O
graft 195 200 579 584 B-chronic_disease
versus 201 207 585 591 I-chronic_disease
host 208 212 592 596 I-chronic_disease
disease 213 220 597 604 I-chronic_disease
( 221 222 605 606 I-chronic_disease
GVHD 222 226 606 610 I-chronic_disease
) 226 227 610 611 I-chronic_disease
and 228 231 612 615 O
no 232 234 616 618 O
requirement 235 246 619 630 O
for 247 250 631 634 O
immunosuppression 251 268 635 652 B-treatment

Anti 0 4 653 657 B-treatment
- 4 5 657 658 I-treatment
cancer 5 11 658 664 I-treatment
agents 12 18 665 671 I-treatment
not 19 22 672 675 O
known 23 28 676 681 O
to 29 31 682 684 O
be 32 34 685 687 O
myelosuppressive 35 51 688 704 B-cancer
( 52 53 705 706 O
e.g. 53 57 706 710 O
not 58 61 711 714 O
associated 62 72 715 725 O
with 73 77 726 730 O
reduced 78 85 731 738 O
platelet 86 94 739 747 O
or 95 97 748 750 O
absolute 98 106 751 759 O
neutrophil 107 117 760 770 O
count 118 123 771 776 O
[ 124 125 777 778 O
ANC 125 128 778 781 O
] 128 129 781 782 O
counts 130 136 783 789 O
): 136 138 789 791 O
At 139 141 792 794 O
least 142 147 795 800 O
7 148 149 801 802 B-lower_bound
days 150 154 803 807 I-lower_bound
after 155 160 808 813 O
the 161 164 814 817 O
last 165 169 818 822 O
dose 170 174 823 827 O
of 175 177 828 830 O
agent 178 183 831 836 O

Antibodies 0 10 837 847 B-clinical_variable
: 10 11 847 848 O
> 12 13 849 850 O
= 13 14 850 851 O
21 15 17 852 854 B-lower_bound
days 18 22 855 859 I-lower_bound
must 23 27 860 864 O
have 28 32 865 869 O
elapsed 33 40 870 877 O
from 41 45 878 882 O
infusion 46 54 883 891 O
of 55 57 892 894 O
last 58 62 895 899 O
dose 63 67 900 904 O
of 68 70 905 907 O
antibody 71 79 908 916 O
, 79 80 916 917 O
and 81 84 918 921 O
toxicity 85 93 922 930 O
related 94 101 931 938 O
to 102 104 939 941 O
prior 105 110 942 947 B-treatment
antibody 111 119 948 956 I-treatment
therapy 120 127 957 964 I-treatment
must 128 132 965 969 O
be 133 135 970 972 O
recovered 136 145 973 982 O
to 146 148 983 985 O
grade 149 154 986 991 B-clinical_variable
= 155 156 992 993 O
< 156 157 993 994 O
1 158 159 995 996 O

At 0 2 997 999 O
least 3 8 1000 1005 O
21 9 11 1006 1008 B-lower_bound
days 12 16 1009 1013 I-lower_bound
after 17 22 1014 1019 O
the 23 26 1020 1023 O
last 27 31 1024 1028 O
dose 32 36 1029 1033 O
of 37 39 1034 1036 O
cytotoxic 40 49 1037 1046 B-treatment
or 50 52 1047 1049 O
myelosuppressive 53 69 1050 1066 B-treatment
chemotherapy 70 82 1067 1079 I-treatment
( 83 84 1080 1081 O
42 84 86 1081 1083 O
days 87 91 1084 1088 O
if 92 94 1089 1091 O
prior 95 100 1092 1097 O
nitrosourea 101 112 1098 1109 B-cancer
) 112 113 1109 1110 O

Autologous 0 10 1111 1121 B-treatment
stem 11 15 1122 1126 I-treatment
cell 16 20 1127 1131 I-treatment
infusion 21 29 1132 1140 I-treatment
including 30 39 1141 1150 O
boost 40 45 1151 1156 B-treatment
infusion 46 54 1157 1165 I-treatment
: 54 55 1165 1166 O
> 56 57 1167 1168 O
= 57 58 1168 1169 O
42 59 61 1170 1172 B-lower_bound
days 62 66 1173 1177 I-lower_bound

Bilirubin 0 9 1178 1187 B-clinical_variable
( 10 11 1188 1189 I-clinical_variable
sum 11 14 1189 1192 I-clinical_variable
of 15 17 1193 1195 I-clinical_variable
conjugated 18 28 1196 1206 I-clinical_variable
+ 29 30 1207 1208 I-clinical_variable
unconjugated 31 43 1209 1221 I-clinical_variable
) 43 44 1221 1222 I-clinical_variable
= 45 46 1223 1224 O
< 46 47 1224 1225 O
1.5 48 51 1226 1229 B-upper_bound
x 52 53 1230 1231 I-upper_bound
upper 54 59 1232 1237 I-upper_bound
limit 60 65 1238 1243 I-upper_bound
of 66 68 1244 1246 I-upper_bound
normal 69 75 1247 1253 I-upper_bound
( 76 77 1254 1255 I-upper_bound
ULN 77 80 1255 1258 I-upper_bound
) 80 81 1258 1259 I-upper_bound
for 82 85 1260 1263 O
age 86 89 1264 1267 B-age

Cellular 0 8 1268 1276 B-treatment
therapy 9 16 1277 1284 I-treatment
: 16 17 1284 1285 O
> 18 19 1286 1287 O
= 19 20 1287 1288 O
42 21 23 1289 1291 B-lower_bound
days 24 28 1292 1296 I-lower_bound
must 29 33 1297 1301 O
have 34 38 1302 1306 O
elapsed 39 46 1307 1314 O
since 47 52 1315 1320 O
the 53 56 1321 1324 O
completion 57 67 1325 1335 O
of 68 70 1336 1338 O
any 71 74 1339 1342 O
type 75 79 1343 1347 O
of 80 82 1348 1350 O
cellular 83 91 1351 1359 B-treatment
therapy 92 99 1360 1367 I-treatment
( 100 101 1368 1369 O
e.g. 101 105 1369 1373 O
modified 106 114 1374 1382 B-treatment
T 115 116 1383 1384 I-treatment
cells 117 122 1385 1390 I-treatment
, 122 123 1390 1391 O
natural 124 131 1392 1399 B-treatment
killer 132 138 1400 1406 I-treatment
[ 139 140 1407 1408 I-treatment
NK 140 142 1408 1410 I-treatment
] 142 143 1410 1411 I-treatment
cells 144 149 1412 1417 I-treatment
, 149 150 1417 1418 O
dendritic 151 160 1419 1428 B-treatment
cells 161 166 1429 1434 I-treatment
, 166 167 1434 1435 O
etc 168 171 1436 1439 O
. 171 172 1439 1440 O
) 172 173 1440 1441 O

Corrected 0 9 1442 1451 B-clinical_variable
QT 10 12 1452 1454 I-clinical_variable
interval 13 21 1455 1463 I-clinical_variable
( 22 23 1464 1465 I-clinical_variable
QTC 23 26 1465 1468 I-clinical_variable
) 26 27 1468 1469 I-clinical_variable
= 28 29 1470 1471 O
< 29 30 1471 1472 O
480 31 34 1473 1476 B-upper_bound
msec 35 39 1477 1481 I-upper_bound

Creatinine 0 10 1482 1492 B-clinical_variable
clearance 11 20 1493 1502 I-clinical_variable
or 21 23 1503 1505 O
radioisotope 24 36 1506 1518 B-clinical_variable
glomerular 37 47 1519 1529 I-clinical_variable
filtration 48 58 1530 1540 I-clinical_variable
rate 59 63 1541 1545 I-clinical_variable
( 64 65 1546 1547 I-clinical_variable
GFR 65 68 1547 1550 I-clinical_variable
) 68 69 1550 1551 I-clinical_variable
> 70 71 1552 1553 O
= 71 72 1553 1554 O
70 73 75 1555 1557 B-lower_bound
ml 76 78 1558 1560 I-lower_bound
/ 78 79 1560 1561 I-lower_bound
min/1.73 79 87 1561 1569 I-lower_bound
m^2 88 91 1570 1573 I-lower_bound
or 92 94 1574 1576 O
a 95 96 1577 1578 O
serum 97 102 1579 1584 B-clinical_variable
creatinine 103 113 1585 1595 I-clinical_variable
based 114 119 1596 1601 O
on 120 122 1602 1604 O
age 123 126 1605 1608 B-age
/ 126 127 1608 1609 O
gender 127 133 1609 1615 O

Cytotoxic 0 9 1616 1625 B-treatment
chemotherapy 10 22 1626 1638 I-treatment
or 23 25 1639 1641 O
other 26 31 1642 1647 O
anti 32 36 1648 1652 B-treatment
- 36 37 1652 1653 I-treatment
cancer 37 43 1653 1659 I-treatment
agents 44 50 1660 1666 I-treatment
known 51 56 1667 1672 O
to 57 59 1673 1675 O
be 60 62 1676 1678 O
myelosuppressive 63 79 1679 1695 O

External 0 8 1696 1704 B-treatment
beam 9 13 1705 1709 I-treatment
radiation 14 23 1710 1719 I-treatment
therapy 24 31 1720 1727 I-treatment
( 32 33 1728 1729 I-treatment
XRT)/external 33 46 1729 1742 I-treatment
beam 47 51 1743 1747 I-treatment
irradiation 52 63 1748 1759 I-treatment
including 64 73 1760 1769 O
protons 74 81 1770 1777 O
: 81 82 1777 1778 O
> 83 84 1779 1780 O
= 84 85 1780 1781 O
14 86 88 1782 1784 B-lower_bound
days 89 93 1785 1789 I-lower_bound
after 94 99 1790 1795 I-lower_bound
local 100 105 1796 1801 O
XRT 106 109 1802 1805 O
; 109 110 1805 1806 O
> 111 112 1807 1808 O
= 112 113 1808 1809 O
150 114 117 1810 1813 B-lower_bound
days 118 122 1814 1818 I-lower_bound
after 123 128 1819 1824 I-lower_bound
total 129 134 1825 1830 B-treatment
body 135 139 1831 1835 I-treatment
irradiation 140 151 1836 1847 I-treatment
( 152 153 1848 1849 I-treatment
TBI 153 156 1849 1852 I-treatment
) 156 157 1852 1853 I-treatment
, 157 158 1853 1854 O
craniospinal 159 171 1855 1867 B-treatment
XRT 172 175 1868 1871 I-treatment
or 176 178 1872 1874 O
if 179 181 1875 1877 O
radiation 182 191 1878 1887 O
to 192 194 1888 1890 O
> 195 196 1891 1892 O
= 196 197 1892 1893 O
50 198 200 1894 1896 B-lower_bound
% 200 201 1896 1897 I-lower_bound
of 202 204 1898 1900 O
the 205 208 1901 1904 O
pelvis 209 215 1905 1911 O

For 0 3 1912 1915 O
patients 4 12 1916 1924 O
with 13 17 1925 1929 O
solid 18 23 1930 1935 B-cancer
tumors 24 30 1936 1942 I-cancer
without 31 38 1943 1950 O
known 39 44 1951 1956 O
bone 45 49 1957 1961 O
marrow 50 56 1962 1968 O
involvement 57 68 1969 1980 O

Hematopoietic 0 13 1981 1994 O
growth 14 20 1995 2001 O
factors 21 28 2002 2009 O
: 28 29 2009 2010 O
At 30 32 2011 2013 O
least 33 38 2014 2019 O
14 39 41 2020 2022 B-lower_bound
days 42 46 2023 2027 I-lower_bound
after 47 52 2028 2033 I-lower_bound
the 53 56 2034 2037 O
last 57 61 2038 2042 O
dose 62 66 2043 2047 O
of 67 69 2048 2050 O
a 70 71 2051 2052 O
long 72 76 2053 2057 O
- 76 77 2057 2058 O
acting 77 83 2058 2064 O
growth 84 90 2065 2071 O
factor 91 97 2072 2078 O
( 98 99 2079 2080 O
e.g. 99 103 2080 2084 O
pegfilgrastim 104 117 2085 2098 B-treatment
) 117 118 2098 2099 O
or 119 121 2100 2102 O
7 122 123 2103 2104 B-upper_bound
days 124 128 2105 2109 I-upper_bound
for 129 132 2110 2113 O
short 133 138 2114 2119 O
- 138 139 2119 2120 O
acting 139 145 2120 2126 O
growth 146 152 2127 2133 O
factor 153 159 2134 2140 O
; 159 160 2140 2141 O
for 161 164 2142 2145 O
agents 165 171 2146 2152 O
that 172 176 2153 2157 O
have 177 181 2158 2162 O
known 182 187 2163 2168 O
adverse 188 195 2169 2176 O
events 196 202 2177 2183 O
occurring 203 212 2184 2193 O
beyond 213 219 2194 2200 O
7 220 221 2201 2202 B-lower_bound
days 222 226 2203 2207 I-lower_bound
after 227 232 2208 2213 I-lower_bound
administration 233 247 2214 2228 O
, 247 248 2228 2229 O
this 249 253 2230 2234 O
period 254 260 2235 2241 O
must 261 265 2242 2246 O
be 266 268 2247 2249 O
extended 269 277 2250 2258 O
beyond 278 284 2259 2265 O
the 285 288 2266 2269 O
time 289 293 2270 2274 O
during 294 300 2275 2281 O
which 301 306 2282 2287 O
adverse 307 314 2288 2295 O
events 315 321 2296 2302 O
are 322 325 2303 2306 O
known 326 331 2307 2312 O
to 332 334 2313 2315 O
occur 335 340 2316 2321 O
; 340 341 2321 2322 O
the 342 345 2323 2326 O
duration 346 354 2327 2335 O
of 355 357 2336 2338 O
this 358 362 2339 2343 O
interval 363 371 2344 2352 O
must 372 376 2353 2357 O
be 377 379 2358 2360 O
discussed 380 389 2361 2370 O
with 390 394 2371 2375 O
the 395 398 2376 2379 O
study 399 404 2380 2385 O
chair 405 410 2386 2391 O

Interleukins 0 12 2392 2404 B-treatment
, 12 13 2404 2405 O
interferons 14 25 2406 2417 B-treatment
and 26 29 2418 2421 O
cytokines 30 39 2422 2431 B-treatment
( 40 41 2432 2433 O
other 41 46 2433 2438 O
than 47 51 2439 2443 O
hematopoietic 52 65 2444 2457 O
growth 66 72 2458 2464 O
factors 73 80 2465 2472 O
): 80 82 2472 2474 O
> 83 84 2475 2476 O
= 84 85 2476 2477 O
21 86 88 2478 2480 B-lower_bound
days 89 93 2481 2485 I-lower_bound
after 94 99 2486 2491 I-lower_bound
the 100 103 2492 2495 O
completion 104 114 2496 2506 O
of 115 117 2507 2509 O
interleukins 118 130 2510 2522 B-treatment
, 130 131 2522 2523 O
interferon 132 142 2524 2534 O
or 143 145 2535 2537 O
cytokines 146 155 2538 2547 O
( 156 157 2548 2549 O
other 157 162 2549 2554 O
than 163 167 2555 2559 O
hematopoietic 168 181 2560 2573 O
growth 182 188 2574 2580 O
factors 189 196 2581 2588 O
) 196 197 2588 2589 O

Karnofsky 0 9 2590 2599 B-clinical_variable
> 10 11 2600 2601 O
= 11 12 2601 2602 O
50 13 15 2603 2605 B-lower_bound
% 15 16 2605 2606 I-lower_bound
for 17 20 2607 2610 O
patients 21 29 2611 2619 O
> 30 31 2620 2621 O
16 32 34 2622 2624 O
years 35 40 2625 2630 O
of 41 43 2631 2633 O
age 44 47 2634 2637 B-age
and 48 51 2638 2641 O
Lansky 52 58 2642 2648 B-clinical_variable
> 59 60 2649 2650 O
= 60 61 2650 2651 O
60 62 64 2652 2654 B-lower_bound
for 65 68 2655 2658 O
patients 69 77 2659 2667 O
= 78 79 2668 2669 O
< 79 80 2669 2670 O
16 81 83 2671 2673 O
years 84 89 2674 2679 O
of 90 92 2680 2682 O
age 93 96 2683 2686 O

No 0 2 2687 2689 O
evidence 3 11 2690 2698 O
of 12 14 2699 2701 O
dyspnea 15 22 2702 2709 B-chronic_disease
at 23 25 2710 2712 O
rest 26 30 2713 2717 O
, 30 31 2717 2718 O
no 32 34 2719 2721 O
exercise 35 43 2722 2730 O
intolerance 44 55 2731 2742 O
due 56 59 2743 2746 O
to 60 62 2747 2749 O
pulmonary 63 72 2750 2759 B-chronic_disease
insufficiency 73 86 2760 2773 I-chronic_disease
, 86 87 2773 2774 O
and 88 91 2775 2778 O
a 92 93 2779 2780 O
pulse 94 99 2781 2786 B-clinical_variable
oximetry 100 108 2787 2795 I-clinical_variable
> 109 110 2796 2797 O
92 111 113 2798 2800 B-lower_bound
% 113 114 2800 2801 I-lower_bound
while 115 120 2802 2807 O
breathing 121 130 2808 2817 O
room 131 135 2818 2822 O
air 136 139 2823 2826 O

Part 0 4 2827 2831 O
B1 5 7 2832 2834 O
: 7 8 2834 2835 O
patients 9 17 2836 2844 O
with 18 22 2845 2849 O
relapsed 23 31 2850 2858 O
or 32 34 2859 2861 O
refractory 35 45 2862 2872 O
neuroblastoma 46 59 2873 2886 B-cancer

Part 0 4 2887 2891 O
B2 5 7 2892 2894 O
: 7 8 2894 2895 O
patients 9 17 2896 2904 O
with 18 22 2905 2909 O
relapsed 23 31 2910 2918 O
or 32 34 2919 2921 O
refractory 35 45 2922 2932 O
osteosarcoma 46 58 2933 2945 B-cancer

Part 0 4 2946 2950 O
B3 5 7 2951 2953 O
: 7 8 2953 2954 O
patients 9 17 2955 2963 O
with 18 22 2964 2968 O
relapsed 23 31 2969 2977 O
or 32 34 2978 2980 O
refractory 35 45 2981 2991 O
rhabdomyosarcoma 46 62 2992 3008 B-cancer

Part 0 4 3009 3013 O
B4 5 7 3014 3016 O
: 7 8 3016 3017 O
patients 9 17 3018 3026 O
with 18 22 3027 3031 O
relapsed 23 31 3032 3040 O
or 32 34 3041 3043 O
refractory 35 45 3044 3054 O
Ewing 46 51 3055 3060 B-cancer
sarcoma 52 59 3061 3068 I-cancer
or 60 62 3069 3071 O
peripheral 63 73 3072 3082 B-cancer
primitive 74 83 3083 3092 I-cancer
neuroectodermal 84 99 3093 3108 I-cancer
tumor 100 105 3109 3114 I-cancer
( 106 107 3115 3116 I-cancer
PNET 107 111 3116 3120 I-cancer
) 111 112 3120 3121 I-cancer

Part 0 4 3122 3126 O
B5 5 7 3127 3129 O
: 7 8 3129 3130 O
patients 9 17 3131 3139 O
with 18 22 3140 3144 O
relapsed 23 31 3145 3153 O
or 32 34 3154 3156 O
refractory 35 45 3157 3167 O
Hodgkin 46 53 3168 3175 B-cancer
lymphoma 54 62 3176 3184 I-cancer

Part 0 4 3185 3189 O
B6 5 7 3190 3192 O
: 7 8 3192 3193 O
patients 9 17 3194 3202 O
with 18 22 3203 3207 O
relapsed 23 31 3208 3216 O
or 32 34 3217 3219 O
refractory 35 45 3220 3230 O
non 46 49 3231 3234 B-cancer
- 49 50 3234 3235 I-cancer
Hodgkin 50 57 3235 3242 I-cancer
lymphoma 58 66 3243 3251 I-cancer

Part 0 4 3252 3256 O
B7 5 7 3257 3259 O
: 7 8 3259 3260 O
patients 9 17 3261 3269 O
must 18 22 3270 3274 O
be 23 25 3275 3277 O
> 26 27 3278 3279 O
= 27 28 3279 3280 O
12 29 31 3281 3283 B-lower_bound
months 32 38 3284 3290 I-lower_bound
and 39 42 3291 3294 O
< 43 44 3295 3296 O
18 45 47 3297 3299 B-upper_bound
years 48 53 3300 3305 I-upper_bound
of 54 56 3306 3308 O
age 57 60 3309 3312 B-age
at 61 63 3313 3315 O
the 64 67 3316 3319 O
time 68 72 3320 3324 O
of 73 75 3325 3327 O
study 76 81 3328 3333 O
enrollment 82 92 3334 3344 O

Part 0 4 3345 3349 O
B7 5 7 3350 3352 O
: 7 8 3352 3353 O
patients 9 17 3354 3362 O
with 18 22 3363 3367 O
unresectable 23 35 3368 3380 B-cancer
melanoma 36 44 3381 3389 I-cancer
or 45 47 3390 3392 O
metastatic 48 58 3393 3403 B-cancer
melanoma 59 67 3404 3412 I-cancer
or 68 70 3413 3415 O
relapsed 71 79 3416 3424 O
melanoma 80 88 3425 3433 O
or 89 91 3434 3436 O
refractory 92 102 3437 3447 B-cancer
melanoma 103 111 3448 3456 I-cancer

Part 0 4 3457 3461 O
B8 5 7 3462 3464 O
: 7 8 3464 3465 O
Patients 9 17 3466 3474 O
with 18 22 3475 3479 O
relapsed 23 31 3480 3488 O
or 32 34 3489 3491 O
refractory 35 45 3492 3502 O
neuroblastoma 46 59 3503 3516 B-cancer
( 60 61 3517 3518 O
MIBG 61 65 3518 3522 O
evaluable 66 75 3523 3532 O
disease 76 83 3533 3540 O
without 84 91 3541 3548 O
Response 92 100 3549 3557 O
Evaluation 101 111 3558 3568 O
Criteria 112 120 3569 3577 O
in 121 123 3578 3580 O
Solid 124 129 3581 3586 O
Tumors 130 136 3587 3593 O
[ 137 138 3594 3595 O
RECIST 138 144 3595 3601 O
] 144 145 3601 3602 O
measurable 146 156 3603 3613 O
lesion 157 163 3614 3620 O
) 163 164 3620 3621 O

Part 0 4 3622 3626 O
D1 5 7 3627 3629 O
: 7 8 3629 3630 O
Patients 9 17 3631 3639 O
with 18 22 3640 3644 O
relapsed 23 31 3645 3653 O
or 32 34 3654 3656 O
refractory 35 45 3657 3667 O
neuroblastoma 46 59 3668 3681 B-chronic_disease

Part 0 4 3682 3686 O
D2 5 7 3687 3689 O
: 7 8 3689 3690 O
Patients 9 17 3691 3699 O
with 18 22 3700 3704 O
relapsed 23 31 3705 3713 O
or 32 34 3714 3716 O
refractory 35 45 3717 3727 O
osteosarcoma 46 58 3728 3740 B-cancer

Part 0 4 3741 3745 O
D3 5 7 3746 3748 O
: 7 8 3748 3749 O
Patients 9 17 3750 3758 O
with 18 22 3759 3763 O
relapsed 23 31 3764 3772 O
or 32 34 3773 3775 O
refractory 35 45 3776 3786 O
rhabdomyosarcoma 46 62 3787 3803 B-cancer

Part 0 4 3804 3808 O
D4 5 7 3809 3811 O
: 7 8 3811 3812 O
Patients 9 17 3813 3821 O
with 18 22 3822 3826 O
relapsed 23 31 3827 3835 O
or 32 34 3836 3838 O
refractory 35 45 3839 3849 O
Ewing 46 51 3850 3855 B-cancer
sarcoma 52 59 3856 3863 I-cancer
or 60 62 3864 3866 O
peripheral 63 73 3867 3877 B-cancer
PNET 74 78 3878 3882 I-cancer

Part 0 4 3883 3887 O
D5 5 7 3888 3890 O
: 7 8 3890 3891 O
Patients 9 17 3892 3900 O
with 18 22 3901 3905 O
relapsed 23 31 3906 3914 O
or 32 34 3915 3917 O
refractory 35 45 3918 3928 O
non 46 49 3929 3932 B-cancer
- 49 50 3932 3933 I-cancer
Hodgkin 50 57 3933 3940 I-cancer
lymphoma 58 66 3941 3949 I-cancer

Part 0 4 3950 3954 O
D6 5 7 3955 3957 O
: 7 8 3957 3958 O
Patients 9 17 3959 3967 O
with 18 22 3968 3972 O
relapsed 23 31 3973 3981 B-cancer
or 32 34 3982 3984 I-cancer
refractory 35 45 3985 3995 I-cancer
neuroblastoma 46 59 3996 4009 I-cancer
( 60 61 4010 4011 O
MIBG 61 65 4011 4015 O
evaluable 66 75 4016 4025 O
disease 76 83 4026 4033 O
without 84 91 4034 4041 O
RECIST 92 98 4042 4048 O
measurable 99 109 4049 4059 O
lesion 110 116 4060 4066 O
) 116 117 4066 4067 O

Part 0 4 4068 4072 O
E3 5 7 4073 4075 O
: 7 8 4075 4076 O
Patients 9 17 4077 4085 O
with 18 22 4086 4090 O
relapsed 23 31 4091 4099 O
or 32 34 4100 4102 O
refractory 35 45 4103 4113 O
rhabdomyosarcoma 46 62 4114 4130 B-cancer

Part 0 4 4131 4135 O
E4 5 7 4136 4138 O
: 7 8 4138 4139 O
Patients 9 17 4140 4148 O
with 18 22 4149 4153 O
relapsed 23 31 4154 4162 O
or 32 34 4163 4165 O
refractory 35 45 4166 4176 O
Ewing 46 51 4177 4182 B-cancer
sarcoma 52 59 4183 4190 I-cancer
or 60 62 4191 4193 O
peripheral 63 73 4194 4204 O
PNET 74 78 4205 4209 B-cancer

Parts 0 5 4210 4215 O
A 6 7 4216 4217 O
& 8 9 4218 4219 O
C 10 11 4220 4221 O
: 11 12 4221 4222 O
patients 13 21 4223 4231 O
must 22 26 4232 4236 O
be 27 29 4237 4239 O
> 30 31 4240 4241 O
= 31 32 4241 4242 O
12 33 35 4243 4245 B-lower_bound
months 36 42 4246 4252 I-lower_bound
and 43 46 4253 4256 O
< 47 48 4257 4258 O
18 49 51 4259 4261 B-upper_bound
years 52 57 4262 4267 I-upper_bound
of 58 60 4268 4270 O
age 61 64 4271 4274 B-age
at 65 67 4275 4277 O
the 68 71 4278 4281 O
time 72 76 4282 4286 O
of 77 79 4287 4289 O
study 80 85 4290 4295 O
enrollment 86 96 4296 4306 O

Parts 0 5 4307 4312 O
A 6 7 4313 4314 O
& 8 9 4315 4316 O
C 10 11 4317 4318 O
: 11 12 4318 4319 O
patients 13 21 4320 4328 O
must 22 26 4329 4333 O
have 27 31 4334 4338 O
either 32 38 4339 4345 O
measurable 39 49 4346 4356 O
or 50 52 4357 4359 O
evaluable 53 62 4360 4369 B-chronic_disease
disease 63 70 4370 4377 I-chronic_disease

Parts 0 5 4378 4383 O
A 6 7 4384 4385 O
& 8 9 4386 4387 O
C 10 11 4388 4389 O
: 11 12 4389 4390 O
patients 13 21 4391 4399 O
with 22 26 4400 4404 O
recurrent 27 36 4405 4414 O
or 37 39 4415 4417 O
refractory 40 50 4418 4428 O
solid 51 56 4429 4434 B-cancer
tumors 57 63 4435 4441 I-cancer
, 63 64 4441 4442 O
without 65 72 4443 4450 O
central 73 80 4451 4458 B-cancer
nervous 81 88 4459 4466 I-cancer
system 89 95 4467 4473 I-cancer
( 96 97 4474 4475 I-cancer
CNS 97 100 4475 4478 I-cancer
) 100 101 4478 4479 I-cancer
tumors 102 108 4480 4486 I-cancer
or 109 111 4487 4489 O
known 112 117 4490 4495 O
CNS 118 121 4496 4499 B-cancer
metastases 122 132 4500 4510 I-cancer

Parts 0 5 4511 4516 O
B1 6 8 4517 4519 O
- 8 9 4519 4520 O
B6 9 11 4520 4522 O
, 11 12 4522 4523 O
B8 13 15 4524 4526 O
, 15 16 4526 4527 O
D1 17 19 4528 4530 O
- 19 20 4530 4531 O
D6 20 22 4531 4533 O
, 22 23 4533 4534 O
E3 24 26 4535 4537 O
, 26 27 4537 4538 O
E4 28 30 4539 4541 O
: 30 31 4541 4542 O
patients 32 40 4543 4551 O
must 41 45 4552 4556 O
be 46 48 4557 4559 O
> 49 50 4560 4561 O
= 50 51 4561 4562 O
12 52 54 4563 4565 B-lower_bound
months 55 61 4566 4572 I-lower_bound
and 62 65 4573 4576 O
= 66 67 4577 4578 O
< 67 68 4578 4579 O
30 69 71 4580 4582 B-upper_bound
years 72 77 4583 4588 I-upper_bound
of 78 80 4589 4591 O
age 81 84 4592 4595 B-age
at 85 87 4596 4598 O
the 88 91 4599 4602 O
time 92 96 4603 4607 O
of 97 99 4608 4610 O
study 100 105 4611 4616 O
enrollment 106 116 4617 4627 O

Parts 0 5 4628 4633 O
C 6 7 4634 4635 O
, 7 8 4635 4636 O
D 9 10 4637 4638 O
, 10 11 4638 4639 O
and 12 15 4640 4643 O
E 16 17 4644 4645 O
: 17 18 4645 4646 O
patients 19 27 4647 4655 O
who 28 31 4656 4659 O
have 32 36 4660 4664 O
received 37 45 4665 4673 O
prior 46 51 4674 4679 B-treatment
ipilimumab 52 62 4680 4690 I-treatment

Patient 0 7 4691 4698 O
's 7 9 4698 4700 O
current 10 17 4701 4708 O
disease 18 25 4709 4716 O
state 26 31 4717 4722 O
must 32 36 4723 4727 O
be 37 39 4728 4730 O
one 40 43 4731 4734 O
for 44 47 4735 4738 O
which 48 53 4739 4744 O
there 54 59 4745 4750 O
is 60 62 4751 4753 O
no 63 65 4754 4756 O
known 66 71 4757 4762 O
curative 72 80 4763 4771 B-treatment
therapy 81 88 4772 4779 I-treatment
or 89 91 4780 4782 O
therapy 92 99 4783 4790 O
proven 100 106 4791 4797 O
to 107 109 4798 4800 O
prolong 110 117 4801 4808 O
survival 118 126 4809 4817 O
with 127 131 4818 4822 O
an 132 134 4823 4825 O
acceptable 135 145 4826 4836 O
quality 146 153 4837 4844 O
of 154 156 4845 4847 O
life 157 161 4848 4852 O

Patients 0 8 4853 4861 O
must 9 13 4862 4866 O
have 14 18 4867 4871 O
fully 19 24 4872 4877 O
recovered 25 34 4878 4887 O
from 35 39 4888 4892 O
the 40 43 4893 4896 O
acute 44 49 4897 4902 O
toxic 50 55 4903 4908 O
effects 56 63 4909 4916 O
of 64 66 4917 4919 O
all 67 70 4920 4923 O
prior 71 76 4924 4929 B-treatment
anti 77 81 4930 4934 I-treatment
- 81 82 4934 4935 I-treatment
cancer 82 88 4935 4941 I-treatment
therapy 89 96 4942 4949 I-treatment
and 97 100 4950 4953 O
must 101 105 4954 4958 O
meet 106 110 4959 4963 O
the 111 114 4964 4967 O
following 115 124 4968 4977 O
minimum 125 132 4978 4985 O
duration 133 141 4986 4994 O
from 142 146 4995 4999 O
prior 147 152 5000 5005 B-treatment
anti 153 157 5006 5010 I-treatment
- 157 158 5010 5011 I-treatment
cancer 158 164 5011 5017 I-treatment
directed 165 173 5018 5026 I-treatment
therapy 174 181 5027 5034 I-treatment
prior 182 187 5035 5040 O
to 188 190 5041 5043 O
enrollment 191 201 5044 5054 O

Patients 0 8 5055 5063 O
must 9 13 5064 5068 O
have 14 18 5069 5073 O
had 19 22 5074 5077 O
histologic 23 33 5078 5088 O
verification 34 46 5089 5101 O
of 47 49 5102 5104 O
malignancy 50 60 5105 5115 B-cancer
at 61 63 5116 5118 O
original 64 72 5119 5127 O
diagnosis 73 82 5128 5137 O
or 83 85 5138 5140 O
relapse 86 93 5141 5148 O

Patients 0 8 5149 5157 O
must 9 13 5158 5162 O
not 14 17 5163 5166 O
have 18 22 5167 5171 O
received 23 31 5172 5180 O
prior 32 37 5181 5186 O
exposure 38 46 5187 5195 O
to 47 49 5196 5198 O
nivolumab 50 59 5199 5208 B-treatment
; 59 60 5208 5209 O
for 61 64 5210 5213 O
patients 65 73 5214 5222 O
enrolled 74 82 5223 5231 O
in 83 85 5232 5234 O
parts 86 91 5235 5240 O
C 92 93 5241 5242 O
, 93 94 5242 5243 O
D 95 96 5244 5245 O
and 97 100 5246 5249 O
E 101 102 5250 5251 O
, 102 103 5251 5252 O
patients 104 112 5253 5261 O
must 113 117 5262 5266 O
not 118 121 5267 5270 O
have 122 126 5271 5275 O
received 127 135 5276 5284 O
prior 136 141 5285 5290 B-treatment
nivolumab 142 151 5291 5300 I-treatment
or 152 154 5301 5303 O
ipilimumab 155 165 5304 5314 B-treatment

Patients 0 8 5315 5323 O
requiring 9 18 5324 5333 O
daily 19 24 5334 5339 O
systemic 25 33 5340 5348 O
corticosteroids 34 49 5349 5364 B-treatment

Patients 0 8 5365 5373 O
who 9 12 5374 5377 O
are 13 16 5378 5381 O
currently 17 26 5382 5391 O
receiving 27 36 5392 5401 O
another 37 44 5402 5409 O
investigational 45 60 5410 5425 B-treatment
drug 61 65 5426 5430 I-treatment

Patients 0 8 5431 5439 O
who 9 12 5440 5443 O
are 13 16 5444 5447 O
currently 17 26 5448 5457 O
receiving 27 36 5458 5467 O
other 37 42 5468 5473 B-treatment
anti 43 47 5474 5478 I-treatment
- 47 48 5478 5479 I-treatment
cancer 48 54 5479 5485 I-treatment
agents 55 61 5486 5492 I-treatment

Patients 0 8 5493 5501 O
who 9 12 5502 5505 O
have 13 17 5506 5510 O
received 18 26 5511 5519 O
prior 27 32 5520 5525 B-treatment
anti 33 37 5526 5530 I-treatment
- 37 38 5530 5531 I-treatment
PD1 38 41 5531 5534 I-treatment
directed 42 50 5535 5543 I-treatment
therapy 51 58 5544 5551 I-treatment
( 59 60 5552 5553 O
monoclonal 60 70 5553 5563 O
antibody 71 79 5564 5572 O
[ 80 81 5573 5574 O
mAb 81 84 5574 5577 O
] 84 85 5577 5578 O
or 86 88 5579 5581 O
small 89 94 5582 5587 O
molecule 95 103 5588 5596 O
) 103 104 5596 5597 O

Patients 0 8 5598 5606 O
who 9 12 5607 5610 O
have 13 17 5611 5615 O
received 18 26 5616 5624 O
prior 27 32 5625 5630 B-treatment
solid 33 38 5631 5636 I-treatment
organ 39 44 5637 5642 I-treatment
transplantation 45 60 5643 5658 I-treatment

Patients 0 8 5659 5667 O
with 9 13 5668 5672 O
> 14 15 5673 5674 O
= 15 16 5674 5675 O
grade 17 22 5676 5681 B-lower_bound
2 23 24 5682 5683 I-lower_bound
hypothyroidism 25 39 5684 5698 B-chronic_disease
due 40 43 5699 5702 O
to 44 46 5703 5705 O
history 47 54 5706 5713 O
of 55 57 5714 5716 O
autoimmunity 58 70 5717 5729 O

Patients 0 8 5730 5738 O
with 9 13 5739 5743 O
CNS 14 17 5744 5747 B-cancer
tumors 18 24 5748 5754 I-cancer
or 25 27 5755 5757 O
known 28 33 5758 5763 O
CNS 34 37 5764 5767 B-cancer
metastases 38 48 5768 5778 I-cancer

Patients 0 8 5779 5787 O
with 9 13 5788 5792 O
a 14 15 5793 5794 O
history 16 23 5795 5802 O
of 24 26 5803 5805 O
congestive 27 37 5806 5816 B-chronic_disease
heart 38 43 5817 5822 I-chronic_disease
failure 44 51 5823 5830 I-chronic_disease
( 52 53 5831 5832 I-chronic_disease
CHF 53 56 5832 5835 I-chronic_disease
) 56 57 5835 5836 I-chronic_disease
or 58 60 5837 5839 O
are 61 64 5840 5843 O
at 65 67 5844 5846 O
risk 68 72 5847 5851 O
because 73 80 5852 5859 O
of 81 83 5860 5862 O
underlying 84 94 5863 5873 O
cardiovascular 95 109 5874 5888 B-chronic_disease
disease 110 117 5889 5896 I-chronic_disease
or 118 120 5897 5899 O
exposure 121 129 5900 5908 O
to 130 132 5909 5911 O
cardiotoxic 133 144 5912 5923 B-treatment
drugs 145 150 5924 5929 I-treatment
must 151 155 5930 5934 O
have 156 160 5935 5939 O
adequate 161 169 5940 5948 O
cardiac 170 177 5949 5956 O
function 178 186 5957 5965 O
as 187 189 5966 5968 O
clinically 190 200 5969 5979 O
indicated 201 210 5980 5989 O

Patients 0 8 5990 5998 O
with 9 13 5999 6003 O
known 14 19 6004 6009 O
bone 20 24 6010 6014 B-cancer
marrow 25 31 6015 6021 I-cancer
metastatic 32 42 6022 6032 I-cancer
disease 43 50 6033 6040 I-cancer
will 51 55 6041 6045 O
be 56 58 6046 6048 O
eligible 59 67 6049 6057 O
for 68 71 6058 6061 O
study 72 77 6062 6067 O
provided 78 86 6068 6076 O
they 87 91 6077 6081 O
meet 92 96 6082 6086 O
the 97 100 6087 6090 O
blood 101 106 6091 6096 O
counts 107 113 6097 6103 O
above 114 119 6104 6109 O
( 120 121 6110 6111 O
may 121 124 6111 6114 O
receive 125 132 6115 6122 O
transfusions 133 145 6123 6135 O
provided 146 154 6136 6144 O
they 155 159 6145 6149 O
are 160 163 6150 6153 O
not 164 167 6154 6157 O
known 168 173 6158 6163 O
to 174 176 6164 6166 O
be 177 179 6167 6169 O
refractory 180 190 6170 6180 O
to 191 193 6181 6183 O
red 194 197 6184 6187 O
cell 198 202 6188 6192 O
or 203 205 6193 6195 O
platelet 206 214 6196 6204 B-treatment
transfusions 215 227 6205 6217 I-treatment
) 227 228 6217 6218 O

Patients 0 8 6219 6227 O
with 9 13 6228 6232 O
known 14 19 6233 6238 O
human 20 25 6239 6244 B-chronic_disease
immunodeficiency 26 42 6245 6261 I-chronic_disease
virus 43 48 6262 6267 I-chronic_disease
( 49 50 6268 6269 I-chronic_disease
HIV 50 53 6269 6272 I-chronic_disease
) 53 54 6272 6273 I-chronic_disease
or 55 57 6274 6276 O
hepatitis 58 67 6277 6286 B-chronic_disease
B 68 69 6287 6288 I-chronic_disease
or 70 72 6289 6291 O
C 73 74 6292 6293 B-chronic_disease

Peripheral 0 10 6294 6304 O
absolute 11 19 6305 6313 B-clinical_variable
neutrophil 20 30 6314 6324 I-clinical_variable
count 31 36 6325 6330 I-clinical_variable
( 37 38 6331 6332 I-clinical_variable
ANC 38 41 6332 6335 I-clinical_variable
) 41 42 6335 6336 I-clinical_variable
> 43 44 6337 6338 O
= 44 45 6338 6339 O
750 46 49 6340 6343 B-lower_bound
/ 49 50 6343 6344 I-lower_bound
mm^3 50 54 6344 6348 I-lower_bound

Platelet 0 8 6349 6357 B-clinical_variable
count 9 14 6358 6363 I-clinical_variable
> 15 16 6364 6365 O
= 16 17 6365 6366 O
75,000 18 24 6367 6373 B-lower_bound
/ 24 25 6373 6374 I-lower_bound
mm^3 25 29 6374 6378 I-lower_bound
( 30 31 6379 6380 O
transfusion 31 42 6380 6391 O
independent 43 54 6392 6403 O
, 54 55 6403 6404 O
defined 56 63 6405 6412 O
as 64 66 6413 6415 O
not 67 70 6416 6419 O
receiving 71 80 6420 6429 O
platelet 81 89 6430 6438 B-treatment
transfusions 90 102 6439 6451 I-treatment
for 103 106 6452 6455 O
at 107 109 6456 6458 O
least 110 115 6459 6464 O
7 116 117 6465 6466 B-lower_bound
days 118 122 6467 6471 I-lower_bound
prior 123 128 6472 6477 I-lower_bound
to 129 131 6478 6480 O
enrollment 132 142 6481 6491 O
) 142 143 6491 6492 O

Pregnant 0 8 6493 6501 B-pregnancy
or 9 11 6502 6504 O
breast 12 18 6505 6511 O
- 18 19 6511 6512 O
feeding 19 26 6512 6519 O
women 27 32 6520 6525 B-gender
will 33 37 6526 6530 O
not 38 41 6531 6534 O
be 42 44 6535 6537 O
entered 45 52 6538 6545 O
on 53 55 6546 6548 O
this 56 60 6549 6553 O
study 61 66 6554 6559 O
due 67 70 6560 6563 O
to 71 73 6564 6566 O
risks 74 79 6567 6572 O
of 80 82 6573 6575 O
fetal 83 88 6576 6581 O
and 89 92 6582 6585 O
teratogenic 93 104 6586 6597 O
adverse 105 112 6598 6605 O
events 113 119 6606 6612 O
as 120 122 6613 6615 O
there 123 128 6616 6621 O
is 129 131 6622 6624 O
yet 132 135 6625 6628 O
no 136 138 6629 6631 O
available 139 148 6632 6641 O
information 149 160 6642 6653 O
regarding 161 170 6654 6663 O
human 171 176 6664 6669 O
fetal 177 182 6670 6675 O
or 183 185 6676 6678 O
teratogenic 186 197 6679 6690 O
toxicities 198 208 6691 6701 O

Radiopharmaceutical 0 19 6702 6721 B-treatment
therapy 20 27 6722 6729 I-treatment
( 28 29 6730 6731 O
e.g. 29 33 6731 6735 O
, 33 34 6735 6736 O
radiolabeled 35 47 6737 6749 B-treatment
antibody 48 56 6750 6758 I-treatment
, 56 57 6758 6759 O
131I 58 62 6760 6764 B-treatment
- 62 63 6764 6765 I-treatment
MIBG 63 67 6765 6769 I-treatment
): 67 69 6769 6771 O
> 70 71 6772 6773 O
= 71 72 6773 6774 O
42 73 75 6775 6777 B-lower_bound
days 76 80 6778 6782 I-lower_bound
must 81 85 6783 6787 O
have 86 90 6788 6792 O
elapsed 91 98 6793 6800 O
since 99 104 6801 6806 O
systemically 105 117 6807 6819 O
administered 118 130 6820 6832 O
radiopharmaceutical 131 150 6833 6852 B-treatment
therapy 151 158 6853 6860 I-treatment

Serum 0 5 6861 6866 B-clinical_variable
glutamate 6 15 6867 6876 I-clinical_variable
pyruvate 16 24 6877 6885 I-clinical_variable
transaminase 25 37 6886 6898 I-clinical_variable
( 38 39 6899 6900 I-clinical_variable
SGPT 39 43 6900 6904 I-clinical_variable
) 43 44 6904 6905 I-clinical_variable
( 45 46 6906 6907 O
alanine 46 53 6907 6914 B-clinical_variable
aminotransferase 54 70 6915 6931 I-clinical_variable
[ 71 72 6932 6933 I-clinical_variable
ALT 72 75 6933 6936 I-clinical_variable
] 75 76 6936 6937 I-clinical_variable
) 76 77 6937 6938 O
= 78 79 6939 6940 O
< 79 80 6940 6941 O
135 81 84 6942 6945 B-upper_bound
U 85 86 6946 6947 I-upper_bound
/ 86 87 6947 6948 I-upper_bound
L 87 88 6948 6949 I-upper_bound

Serum 0 5 6950 6955 B-clinical_variable
lipase 6 12 6956 6962 I-clinical_variable
= 13 14 6963 6964 O
< 14 15 6964 6965 O
ULN 16 19 6966 6969 O
at 20 22 6970 6972 O
baseline 23 31 6973 6981 O
; 31 32 6981 6982 O
patients 33 41 6983 6991 O
with 42 46 6992 6996 O
glucose 47 54 6997 7004 B-chronic_disease
intolerance 55 66 7005 7016 I-chronic_disease
should 67 73 7017 7023 O
be 74 76 7024 7026 O
on 77 79 7027 7029 O
a 80 81 7030 7031 O
stable 82 88 7032 7038 O
regimen 89 96 7039 7046 O
and 97 100 7047 7050 O
be 101 103 7051 7053 O
monitored 104 113 7054 7063 O

Shortening 0 10 7064 7074 B-clinical_variable
fraction 11 19 7075 7083 I-clinical_variable
of 20 22 7084 7086 O
> 23 24 7087 7088 O
= 24 25 7088 7089 O
27 26 28 7090 7092 B-lower_bound
% 28 29 7092 7093 I-lower_bound
by 30 32 7094 7096 O
echocardiogram 33 47 7097 7111 B-treatment
or 48 50 7112 7114 O
ejection 51 59 7115 7123 B-clinical_variable
fraction 60 68 7124 7132 I-clinical_variable
of 69 71 7133 7135 O
> 72 73 7136 7137 O
= 73 74 7137 7138 O
50 75 77 7139 7141 B-lower_bound
% 77 78 7141 7142 I-lower_bound
by 79 81 7143 7145 O
gated 82 87 7146 7151 O
radionuclide 88 100 7152 7164 O
study 101 106 7165 7170 O

Stem 0 4 7171 7175 B-treatment
cell 5 9 7176 7180 I-treatment
infusion 10 18 7181 7189 I-treatment

melanoma 0 8 7190 7198 B-cancer
patients 9 17 7199 7207 O
in 18 20 7208 7210 O
Part 21 25 7211 7215 O
B7 26 28 7216 7218 O
must 29 33 7219 7223 O
have 34 38 7224 7228 O
either 39 45 7229 7235 O
measurable 46 56 7236 7246 O
or 57 59 7247 7249 O
evaluable 60 69 7250 7259 O
disease 70 77 7260 7267 O

neuroblastoma 0 13 7268 7281 O
patients 14 22 7282 7290 O
in 23 25 7291 7293 O
Parts 26 31 7294 7299 O
B8 32 34 7300 7302 O
and 35 38 7303 7306 O
D6 39 41 7307 7309 O
must 42 46 7310 7314 O
be 47 49 7315 7317 O
evaluable 50 59 7318 7327 O
for 60 63 7328 7331 O
MIBG 64 68 7332 7336 B-treatment
response 69 77 7337 7345 O
without 78 85 7346 7353 O
evidence 86 94 7354 7362 O
of 95 97 7363 7365 O
RECIST 98 104 7366 7372 O
measurable 105 115 7373 7383 O
lesions 116 123 7384 7391 O

patients 0 8 7392 7400 O
must 9 13 7401 7405 O
not 14 17 7406 7409 O
have 18 22 7410 7414 O
received 23 31 7415 7423 O
systemic 32 40 7424 7432 B-treatment
corticosteroids 41 56 7433 7448 I-treatment
within 57 63 7449 7455 O
7 64 65 7456 7457 B-upper_bound
days 66 70 7458 7462 I-upper_bound
prior 71 76 7463 7468 I-upper_bound
to 77 79 7469 7471 O
enrollment 80 90 7472 7482 O

patients 0 8 7483 7491 O
with 9 13 7492 7496 O
a 14 15 7497 7498 O
history 16 23 7499 7506 O
of 24 26 7507 7509 O
CNS 27 30 7510 7513 B-cancer
metastases 31 41 7514 7524 I-cancer
that 42 46 7525 7529 O
have 47 51 7530 7534 O
been 52 56 7535 7539 O
previously 57 67 7540 7550 O
treated 68 75 7551 7558 O
may 76 79 7559 7562 O
enroll 80 86 7563 7569 O
if 87 89 7570 7572 O
sequential 90 100 7573 7583 O
imaging 101 108 7584 7591 O
shows 109 114 7592 7597 O
not 115 118 7598 7601 O
evidence 119 127 7602 7610 O
for 128 131 7611 7614 O
active 132 138 7615 7621 O
disease 139 146 7622 7629 O

patients 0 8 7630 7638 O
with 9 13 7639 7643 O
extra 14 19 7644 7649 O
axial 20 25 7650 7655 B-chronic_disease
disease 26 33 7656 7663 I-chronic_disease
( 34 35 7664 7665 O
e.g. 35 39 7665 7669 O
skull 40 45 7670 7675 B-cancer
[ 46 47 7676 7677 I-cancer
bone 47 51 7677 7681 I-cancer
] 51 52 7681 7682 I-cancer
metastasis 53 63 7683 7693 I-cancer
that 64 68 7694 7698 O
do 69 71 7699 7701 O
not 72 75 7702 7705 O
invade 76 82 7706 7712 O
the 83 86 7713 7716 O
dura 87 91 7717 7721 O
) 91 92 7721 7722 O
may 93 96 7723 7726 O
enroll 97 103 7727 7733 O
if 104 106 7734 7736 O
there 107 112 7737 7742 O
is 113 115 7743 7745 O
no 116 118 7746 7748 O
evidence 119 127 7749 7757 O
for 128 131 7758 7761 O
CNS 132 135 7762 7765 O
edema 136 141 7766 7771 O
associated 142 152 7772 7782 O
with 153 157 7783 7787 O
the 158 161 7788 7791 O
lesion 162 168 7792 7798 O

pregnancy 0 9 7799 7808 B-pregnancy
tests 10 15 7809 7814 O
must 16 20 7815 7819 O
be 21 23 7820 7822 O
obtained 24 32 7823 7831 O
in 33 35 7832 7834 O
girls 36 41 7835 7840 B-gender
who 42 45 7841 7844 O
are 46 49 7845 7848 O
post 50 54 7849 7853 O
- 54 55 7853 7854 O
menarchal 55 64 7854 7863 O

these 0 5 7864 7869 O
patients 6 14 7870 7878 O
will 15 19 7879 7883 O
not 20 23 7884 7887 O
be 24 26 7888 7890 O
evaluable 27 36 7891 7900 O
for 37 40 7901 7904 O
hematologic 41 52 7905 7916 B-chronic_disease
toxicity 53 61 7917 7925 I-chronic_disease

